Inflammation plays a crucial role in the pathogenesis of cancer with tumor necrosis factor-α (TNF-α) as a key mediator. Recently, spermatogenesis-associated protein 2 (SPATA2) was identified as a TNF receptor modulator which is required for TNFinduced inflammation and apoptosis. The available data on TNF-α in ovarian cancer with reduced progression-free survival (P = 0.048) and overall survival (P < 0.001). In conclusion, SPATA2 expression is regulated by TNF-α and IL-1β and is found to independently affect clinical outcome in OC patients. These data implicate a role of SPATA2 in tumorigenesis which warrants further investigation in gynecological malignancies.
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Inflammation plays a crucial role in the pathogenesis of cancer with tumor necrosis factor-α (TNF-α) as a key mediator. Recently, spermatogenesis-associated protein 2 (SPATA2) was identified as a TNF receptor modulator which is required for TNFinduced inflammation and apoptosis. The available data on TNF-α in ovarian cancer (OC) are inconsistent, and SPATA2 is completely uncharacterized in tumorigenesis.
We analyzed expression of SPATA2 and TNFA by quantitative real-time polymerase chain reaction in tissues of 171 patients with low-grade serous (LGSOC), high-grade serous (HGSOC), endometrioid and clear cell OC compared with 28 non-malignant control tissues. We stimulated OC cells (OVCAR3) with pro-inflammatory (TNF-α, interleukin [IL]-1β) and mitogenic stimuli (IL-6, lysophosphatidic acid) to establish a direct effect between inflammatory signaling and SPATA2. Pro-inflammatory, but not mitogenic stimuli, potently induced SPATA2 expression in OC cells. Expression of TNFA and SPATA2 was higher in OC compared with control tissues (P = 0.010 and P = 0.001, respectively) and correlated with each other (P = 0.034, r s = 0.198). When compared with grade 1 cancers, SPATA2 was expressed higher in grade 2 and 3 tumors (P = 0.011) as well as in HGSOC compared with LGSOC (P = 0.024). Multivariate survival analyses revealed that OC with high SPATA2 expression were associated with reduced progression-free survival (P = 0.048) and overall survival (P < 0.001). In conclusion, SPATA2 expression is regulated by TNF-α and IL-1β and is found to independently affect clinical outcome in OC patients. These data implicate a role of SPATA2 in tumorigenesis which warrants further investigation in gynecological malignancies.
| INTRODUC TI ON
Ovarian cancer is one of the most common cancers amongst women in Europe and the striking cause of death in gynecological cancer entities. 1 In recent years, multiple treatment modalities have emerged including surgical therapy, chemotherapy, antiangiogenic agents and PARP inhibitors. Compared with other tumor entities, immunotherapy has not been established and prognosis remains devastating.
2
These observations highlight the necessity for a better understanding of disease pathogenesis.
The link between inflammation and cancer, which is termed "cancer-related inflammation", has been increasingly emerging over the last decade. 3, 4 It is conceived that malignant processes are fueled by a "smoldering" inflammation in the tumor microenvironment that has many tumor initiating and promoting effects. Cancer-related inflammatory events have been shown to play a crucial role in the pathogenesis of OC. 4, 6 More specifically, OC is characterized by a pro-inflammatory network that acts on the tumor microenvironment thereby affecting not only tumor growth but also leukocyte infiltration and neoangiogenesis in peritoneal tumor deposits. 7 Urinary neopterin, a marker for IFN-induced macrophage activation, overwhelming reflects inflammation and has been shown to be a potent prognostic factor in OC. 8 The use of non-steroidal anti-inflammatory drugs was recently associated with improved survival among 4117 patients with serous tumor histology corroborating the overwhelming inflammatory conditions affecting OC biology and potentially highlighting anti-inflammatory therapies as treatment options especially for HGSOC patients. 9 TNF-α, a key mediator in acute and chronic inflammation, is expressed in the OC microenvironment and seems to promote tumor progression by the induction of cytokines, proangiogenic factors and metalloproteinases. 6 Moreover, TNF-α may be implicated in the control of key disease features including cachexia, depression and fatigue, alters energy metabolism and aggravates tumor anemia 10 and the TNF-α receptor repertoire may play a role in cancer immune-editing through modulation of immune responses.
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Recently, SPATA2 was identified as a novel component of the TNFR1 complex and is required for TNFR1 signaling. 12 More specifically, SPATA2 links two subunits of the TNFR1 pathway, namely CYLD and HOIP, to allow recruitment of CYLD to the TNFR1 receptor upon TNF-α ligation. 13, 14 Moreover, SPATA2 acts as an allosteric activator for CYLD attenuating TNF-induced NF-κB and MAPK signaling 15 suggesting that SPATA2 is required for TNF-induced apoptosis and necroptosis. [13] [14] [15] However, loss of SPATA2 had different effects on the pro-inflammatory TNF signaling, [13] [14] [15] [16] indicating heterogeneous effects on NF-κB activation by TNF-α.
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Tumor necrosis factor-α and downstream-mediated functions in tumorigenesis are context-dependent and incompletely understood for OC. [17] [18] [19] [20] 
| RNA isolation and reverse transcription
Total cellular RNA extraction from tissue samples and in vitro experiments and reverse transcription were performed as previously 
| Immunohistochemistry
Immunohistochemistry was performed using an automated immu- 
| Statistical analysis
The non-parametric Mann-Whitney U-test or Kruskal-Wallis test were applied to test for statistical significance between two groups or more than two groups, respectively. The correlations between SPATA2 and TNFA mRNA expression were assessed by Spearman's rank correlation coefficient analyses. PFS was defined as the time 
| RE SULTS

| TNFA expression correlates with SPATA2 expression in OC tissue
To investigate a potential role of TNF-α and SPATA2 in the biology of OC, we measured SPATA2 and TNFA mRNA levels in tumor tissues of 170 OC patients by quantitative PCR and compared it with 24 non-neoplastic tissues of healthy controls. TNFA expression was elevated in OC tissue compared with non-malignant tubes or ovaries (P = 0.010; Figure 1A ). We further observed higher levels of Figure 2B ).
In OVCAR3 cells, TNF-α and IL-1β induced SPATA2 expression more than FSH with the maximal effect after 3 hours of treatment ( Figure 2C ). LPA and IL-6 (known to induce OC proliferation) 27, 28 did not have an impact on SPATA2 expression (data not shown).
Despite directly correlating with SPATA2 levels at baseline, RNF31
could not be induced by TNF-α and IL-1β, LPA or IL-6. In contrast, CYLD, which is also component of the TNF-R signaling pathway, exhibited similar induction patterns compared with SPATA2. In F I G U R E 1 TNFA and SPATA2 expression is elevated in ovarian cancer (OC) tissue compared with non-neoplastic fallopian tubes. A, TNFA expression in non-neoplastic control tissues (fallopian tubes, n = 7; ovaries, n = 3) and OC (n = 105). B, SPATA2 expression in non-neoplastic control tissues (fallopian tubes, n = 14; ovaries, n = 14) and OC (n = 170). C, Linear regression analysis of TNFA (n = 115) and SPATA2 (n = 198) in non-malignant control tissues and OC. TNFA and SPATA2 mRNA expression values were normalized to TBP expression detail, both SPATA2 and CYLD were induced by TNF-α and IL-1β
(but not FSH) after 3 hours ( Figure 2D ). Our data establish a direct effect of pro-inflammatory cytokines such as TNF-α and IL-1β on SPATA2 expression in human OC cells.
| Increased SPATA2 expression occurred in higher tumor grades
Next, we explored the association between SPATA2 and TNFA expression with clinicopathological features. As demonstrated in Table 1 and Figure 3 , we found that increased SPATA2 expression was associated with higher tumor grade. Specifically, we found higher SPATA2 mRNA levels in tumor grade 2 and 3 compared with tumor grade 1 ( Figure 3A ) which was in line with higher SPATA2 expression in HGSOC compared with LGSOC (P = 0.024; Figure 3B ). In contrast, TNFA expression was not associated with tumor grade and did not differ between histological subtypes (Table 1) . SPATA2 and TNFA expression was independent from FIGO stage.
| High SPATA2 mRNA expression is associated with a poor prognosis
To evaluate SPATA2 and TNFA levels regarding clinical outcome of OC patients, we first determined Youden's index 24 which grouped the OC cohort into patients with "high" and "low" SPATA2 and TNFA expression. Univariate survival analyses (Table 2) Figure 4C ). This was also true for the subgroup analysis of HGSOC (P = 0.002; Figure 4D ).
Importantly, multivariate analyses identified SPATA2 as an independent prognostic factor for PFS (HR, 1.55; P = 0.048; Table 3 ) and OS (HR, 2.13; P < 0.001; Table 3 ). TNFA expression, however, failed to be of prognostic significance either regarding PFS or OS in OC (Table 2 , Figure S2A ,B).
| D ISCUSS I ON
In this study, we investigated the regulation of TNFA and SPATA2 and the impact on clinical outcome in a Caucasian OC cohort. We found that TNFA and SPATA2 are significantly higher expressed in OC com- Tumor necrosis factor-α has been initially discovered as initiator of tumor cell necrosis 21 and is now known as a potent proinflammatory cytokine which exerts deleterious effects in chronic inflammation, antimicrobial immunity and autoimmune diseases. in recurrent OC. 21 However, the same was true when TNF-α itself was used in high pharmacological doses combined with chemotherapy to refine the necrotic activity of TNF-α and to boost antitumor activity. 22 Thus, it appears that TNF-α represents a "double-dealer" with regard to cancer biology. 35 On one hand, TNF-α through its proinflammatory properties could be an endogenous tumor promoter stimulating cancer cell growth, proliferation, metastasis, angiogenesis and leukocyte infiltration; and on the other hand, TNF-α could also act as a killer of cancer cells. These divergent observations may be one reason why more recent studies focused on downstream TNF-α signaling.
A number of investigations have disclosed complex and diverging TNF-R signaling pathways described as a "double-edged" sword.
36
We found that SPATA2, a novel component of the TNFR1 signaling complex, is an independent predictor for adverse PFS and OS in OC patients. SPATA2 is an adaptor for the recruitment of CYLD to the TNF-R signaling cascade and an activator of CYLD which controls TNF-induced apoptosis and necroptosis. [13] [14] [15] Cells lacking SPATA2 exhibited reduced TNF-induced cell death due to reduced caspase-3 suggesting that SPATA2 is required for TNF-induced cell death.
Currently, there are no data on the role of SPATA2 in tumorigenesis and cancer progression. However, CYLD, the co-factor for SPATA2 is a known tumor suppressor 37 shown to inhibit NF-κB, MAPK and Wnt signaling. On the other hand, CYLD also acts as a mediator of immune activation and inflammation. 38, 39 We found that both SPATA2 and CYLD are induced by TNF-α and IL-1β in vitro, indicating a similar regulation in OC. CYLD and SPATA2 were shown to synergistically promote TNF-induced NF-κB signaling, caspase activation and apoptosis. 15 Considering that, OC with high SPATA2 expression levels may also show high rates of apoptosis. In other cancer entities, such as colon carcinoma and breast cancer, high apoptotic rates were associated with increased cellular proliferation and poor prog- proved to predict adverse clinical outcome in OC.
In conclusion, our study suggests a potential biologic role of 
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